WO2003072572A8 - Beta3-adrenergic receptor agonists - Google Patents

Beta3-adrenergic receptor agonists

Info

Publication number
WO2003072572A8
WO2003072572A8 PCT/IB2003/000590 IB0300590W WO03072572A8 WO 2003072572 A8 WO2003072572 A8 WO 2003072572A8 IB 0300590 W IB0300590 W IB 0300590W WO 03072572 A8 WO03072572 A8 WO 03072572A8
Authority
WO
WIPO (PCT)
Prior art keywords
adrenergic receptor
receptor agonists
beta3
disorders
treating
Prior art date
Application number
PCT/IB2003/000590
Other languages
French (fr)
Other versions
WO2003072572A1 (en
Inventor
Jennifer Anne Lafontaine
Bradley Paul Morgan
Original Assignee
Pfizer Prod Inc
Jennifer Anne Lafontaine
Bradley Paul Morgan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Jennifer Anne Lafontaine, Bradley Paul Morgan filed Critical Pfizer Prod Inc
Priority to BR0308070-6A priority Critical patent/BR0308070A/en
Priority to MXPA04007127A priority patent/MXPA04007127A/en
Priority to AU2003248356A priority patent/AU2003248356A1/en
Priority to EP03742884A priority patent/EP1485379A1/en
Priority to CA002476316A priority patent/CA2476316A1/en
Priority to JP2003571278A priority patent/JP2005518448A/en
Publication of WO2003072572A1 publication Critical patent/WO2003072572A1/en
Publication of WO2003072572A8 publication Critical patent/WO2003072572A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention provides β3-adrenergic receptor agonists of structural Formula (I) as well as pharmaceutical formulations thereof and methods for treating β3-adrenergic receptor-mediated diseases, conditions, or disorders using such compounds.
PCT/IB2003/000590 2002-02-27 2003-02-17 Beta3-adrenergic receptor agonists WO2003072572A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0308070-6A BR0308070A (en) 2002-02-27 2003-02-17 Adrenergic beta3 receptor agonists
MXPA04007127A MXPA04007127A (en) 2002-02-27 2003-02-17 Beta3.
AU2003248356A AU2003248356A1 (en) 2002-02-27 2003-02-17 Beta3-adrenergic receptor agonists
EP03742884A EP1485379A1 (en) 2002-02-27 2003-02-17 Beta 3-adrenergic receptor agonists
CA002476316A CA2476316A1 (en) 2002-02-27 2003-02-17 Beta3-adrenergic receptor agonists
JP2003571278A JP2005518448A (en) 2002-02-27 2003-02-17 Beta-3-adrenergic receptor agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27
US60/360,251 2002-02-27

Publications (2)

Publication Number Publication Date
WO2003072572A1 WO2003072572A1 (en) 2003-09-04
WO2003072572A8 true WO2003072572A8 (en) 2004-01-29

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000590 WO2003072572A1 (en) 2002-02-27 2003-02-17 Beta3-adrenergic receptor agonists

Country Status (13)

Country Link
EP (1) EP1485379A1 (en)
JP (1) JP2005518448A (en)
AU (1) AU2003248356A1 (en)
BR (1) BR0308070A (en)
CA (1) CA2476316A1 (en)
DO (1) DOP2003000587A (en)
GT (1) GT200300043A (en)
MX (1) MXPA04007127A (en)
PA (1) PA8567701A1 (en)
PE (1) PE20030943A1 (en)
TW (1) TW200408637A (en)
UY (1) UY27680A1 (en)
WO (1) WO2003072572A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
JP4618250B2 (en) * 2003-12-23 2011-01-26 アステラス製薬株式会社 Amino alcohol derivative
DE102004021779A1 (en) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, process for their preparation and their use as medicines
JP5173190B2 (en) 2004-08-25 2013-03-27 武田薬品工業株式会社 Preventive and therapeutic agent for stress urinary incontinence and screening method thereof
PE20091825A1 (en) 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
EP2771006B1 (en) 2011-10-27 2016-05-25 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
HUE045260T2 (en) 2013-03-15 2019-12-30 Merck Sharp & Dohme Process for preparing beta 3 agonists and intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
KR100327273B1 (en) * 1994-04-08 2002-05-10 고사이 아끼오 Ether compound, use thereof, and intermediate for producing the compound
JPH11504649A (en) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β-adrenergic agonist
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
GT200300043A (en) 2003-09-22
WO2003072572A1 (en) 2003-09-04
UY27680A1 (en) 2003-10-31
AU2003248356A1 (en) 2003-09-09
MXPA04007127A (en) 2005-07-05
PE20030943A1 (en) 2003-11-08
DOP2003000587A (en) 2003-08-30
CA2476316A1 (en) 2003-09-04
BR0308070A (en) 2004-12-21
PA8567701A1 (en) 2003-11-12
TW200408637A (en) 2004-06-01
EP1485379A1 (en) 2004-12-15
JP2005518448A (en) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2005046603A3 (en) Pyridine compounds
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005030678A3 (en) AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS
NO20022655D0 (en) <Beta> -2-adrenergic receptor agonists
WO2004108133A3 (en) Modulators of vr1 receptor
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
WO2006052889A3 (en) Quinolinone-carboxamide compounds
WO2002072536A8 (en) Urea derivatives having vanilloid receptor (vr1) antagonist activity
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
EP1679313A3 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005013914A8 (en) Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
MX2007007220A (en) Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders.
CA2449729A1 (en) Prodrugs of gaba analogs, compositions and uses thereof
WO2004092135A3 (en) Substituted benzosulphonamide as potentiators of glutamate receptors
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2003024928A3 (en) Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
NO20061981L (en) Arylindenopyridines and arylindenopyridines and their use as adenosine A2A receptor agonist
DK1551803T3 (en) Azabicyclo derivatives as muscarinic receptor antagonists
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA05013151A (en) 3-fluoro-piperidines as nmda/nr2b antagonists.
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
WO2003072572A8 (en) Beta3-adrenergic receptor agonists
WO2003057149A3 (en) 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

CFP Corrected version of a pamphlet front page

Free format text: UNDER (57) PUBLISHED ABSTRACT REPLACED BY CORRECT ABSTRACT

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007127

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2476316

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003742884

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003571278

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003742884

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003742884

Country of ref document: EP